Your browser doesn't support javascript.
loading
Assessment of the yellow fever outbreak in Angola from December 2015 through December 2016: A retrospective study.
Manuel, Eusebio; Armando, António; Francisco, Moisés; Paixão, Joana; Aramburu, Javier; de Oliveira, Miguel Dos Santos; Freitas, Helga; Pedro, Alda Morais; Jandondo, Domingos; Carderon, Pablo Babrero; Lamezon, Sandra Lopez; Fortes, Filomeno; Mariscal, Jorge; Cardoso, Yolanda; Moreira, Rosa; Morais, Joana; Francisco, Ngiambudulu M.
Afiliação
  • Manuel E; Faculdade de Medicina Universidade Agostinho Neto Luanda Angola.
  • Armando A; Direcção Nacional de Saúde Pública Ministério da Saúde Luanda Angola.
  • Francisco M; Direcção Nacional de Saúde Pública Ministério da Saúde Luanda Angola.
  • Paixão J; Grupo de Investigação Microbiana e Imunológica Instituto Nacional de Investigação em Saúde (National Institute for Health Research) Luanda Angola.
  • Aramburu J; Grupo de Investigação Microbiana e Imunológica Instituto Nacional de Investigação em Saúde (National Institute for Health Research) Luanda Angola.
  • de Oliveira MDS; World Health Organization (OMS, Angola) Luanda Angola.
  • Freitas H; Direcção Nacional de Saúde Pública Ministério da Saúde Luanda Angola.
  • Pedro AM; Direcção Nacional de Saúde Pública Ministério da Saúde Luanda Angola.
  • Jandondo D; Direcção Nacional de Saúde Pública Ministério da Saúde Luanda Angola.
  • Carderon PB; Grupo de Investigação Microbiana e Imunológica Instituto Nacional de Investigação em Saúde (National Institute for Health Research) Luanda Angola.
  • Lamezon SL; Clínica Girassol Luanda Angola.
  • Fortes F; Direcção Nacional de Saúde Pública Ministério da Saúde Luanda Angola.
  • Mariscal J; Instituto de Higiene e Medicina Tropical Universidade Nova de Lisboa Lisboa Portugal.
  • Cardoso Y; Direcção Nacional de Saúde Pública Ministério da Saúde Luanda Angola.
  • Moreira R; Faculdade de Medicina Universidade Agostinho Neto Luanda Angola.
  • Morais J; Direcção Nacional de Saúde Pública Ministério da Saúde Luanda Angola.
  • Francisco NM; Faculdade de Medicina Universidade Agostinho Neto Luanda Angola.
Health Sci Rep ; 7(2): e1924, 2024 Feb.
Article em En | MEDLINE | ID: mdl-38444843
ABSTRACT
Background and

Aims:

The acute tropical infectious disease known as yellow fever (YF) is caused by an arbovirus and is characterized by fever, jaundice, hemorrhage, headache, muscle pain, nausea, vomiting, and fatigue. Angola experienced a yellow fever virus (YFV) outbreak that was documented in December 2015. However, little is known about the outcome of this outbreak. We aimed to demonstrate epidemic features and lessons learned during the YF epidemic in Angola.

Methods:

A total of 4618 blood samples from suspected YF cases were sent to the Instituto Nacional de Investigação em Saúde (INIS), a national referral and public health laboratory, between December 5, 2015, and December 23, 2016. Sample analyses were conducted using enzyme-linked immunosorbent assay (ELISA) and reverse transcription polymerase chain reaction (RT-PCR) assays. Blood samples were sent from 16 out of the 18 provinces of Angola.

Results:

We detected 884 (19.1%) cases that were positive for ELISA, which were confirmed by RT-PCR assay. Considering the positive cases, the incidence among male patients was around three times higher (n = 223; 10.9%) than in female patients (n = 59; 2.6%) in the 20-29 age group, followed by the age group 10-19 with n = 211 (6.8%) in males versus n = 108 (3.3%) in females; and the age group 30-39 had n = 68 (4.8%) in males versus n = 28 (1.8%) in females. The other groups had an incidence below 3.0%. The case fatality ratio for YF was in young adults in the age group 20-29 with n = 39 cases, followed by the age group 10-19 with n = 16 cases, and finally the age group 0-9 with n = 13 cases. The other age groups had several deaths by YF below 10 cases.

Conclusions:

This study demonstrates features of the YF epidemic that occurred in Angola. Also, it demonstrates that YF causes deaths in young people but is preventable by high vaccine coverage. Thus, public health laboratory surveillance must be strengthened to reduce the possibility of emerging and re-emerging human infections.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Health Sci Rep Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Health Sci Rep Ano de publicação: 2024 Tipo de documento: Article